TY - JOUR
T1 - Socioeconomic disparities in lung cancer treatment and outcomes persist within a single academic medical center
AU - Yorio, Jeffrey T.
AU - Yan, Jingsheng
AU - Xie, Yang
AU - Gerber, David E.
N1 - Funding Information:
Biostatistical support was provided by the Biostatistics Shared Resource at the Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, which is supported in part by a National Cancer Institute Cancer Center Support Grant, 1P30 CA142543-01 .
Funding Information:
Funding was provided by American Cancer Society and Simmons Cancer Center grant ACS-IRG-02-196 , National Institutes of Health CTSA grant KL2RR024983 (North and Central Texas Clinical and Translational Science Initiative), and a National Cancer Institute Clinical Investigator Team Leadership Award ( 1P30 CA142543-01 supplement) (D.E.G.).
PY - 2012/11
Y1 - 2012/11
N2 - Background: Socioeconomic disparities in treatment and outcomes of non-small-cell lung cancer (NSCLC) are well established. To explore whether these differences are secondary to individual or institutional characteristics, we examined treatment selection and outcome in a diverse population treated at a single medical center. Patients and Methods: We performed a retrospective analysis of consecutive patients diagnosed with NSCLC stages I-III from 2000 to 2005 at the University of Texas Southwestern Medical Center. Treatment selection was dichotomized as 'standard' (surgery for stage I-II; surgery and/or radiation therapy for stage III) or 'other.' Associations between patient characteristics (including socioeconomic status) and treatment selection were examined using logistic regression; associations between characteristics and overall survival were examined using Cox regression models and Kaplan-Meier survival analysis. Results: A total of 450 patients were included. Twenty-eight percent of patients had private insurance, 43% had Medicare, and 29% had an indigent care plan. The likelihood of receiving 'standard' therapy was significantly associated with insurance type (indigent plan versus private insurance odds ratio [OR] 0.13, 95% confidence interval [CI] 0.04, 0.43 for stage I-II; OR 0.38, 95% CI 0.14, 1.00 for stage III). For patients with stage I-II NSCLC, survival was associated with age, sex, insurance type (indigent plan versus private insurance hazard ratio for death 1.98; 95% CI 1.16, 3.37), stage, and treatment selection. In stage III NSCLC, survival was associated with treatment selection. Conclusion: Within a single academic medical center, socioeconomically disadvantaged patients with stage I-III NSCLC are less likely to receive 'standard' therapy. Socioeconomically disadvantaged patients with stage I-II NSCLC have inferior survival independent of therapy.
AB - Background: Socioeconomic disparities in treatment and outcomes of non-small-cell lung cancer (NSCLC) are well established. To explore whether these differences are secondary to individual or institutional characteristics, we examined treatment selection and outcome in a diverse population treated at a single medical center. Patients and Methods: We performed a retrospective analysis of consecutive patients diagnosed with NSCLC stages I-III from 2000 to 2005 at the University of Texas Southwestern Medical Center. Treatment selection was dichotomized as 'standard' (surgery for stage I-II; surgery and/or radiation therapy for stage III) or 'other.' Associations between patient characteristics (including socioeconomic status) and treatment selection were examined using logistic regression; associations between characteristics and overall survival were examined using Cox regression models and Kaplan-Meier survival analysis. Results: A total of 450 patients were included. Twenty-eight percent of patients had private insurance, 43% had Medicare, and 29% had an indigent care plan. The likelihood of receiving 'standard' therapy was significantly associated with insurance type (indigent plan versus private insurance odds ratio [OR] 0.13, 95% confidence interval [CI] 0.04, 0.43 for stage I-II; OR 0.38, 95% CI 0.14, 1.00 for stage III). For patients with stage I-II NSCLC, survival was associated with age, sex, insurance type (indigent plan versus private insurance hazard ratio for death 1.98; 95% CI 1.16, 3.37), stage, and treatment selection. In stage III NSCLC, survival was associated with treatment selection. Conclusion: Within a single academic medical center, socioeconomically disadvantaged patients with stage I-III NSCLC are less likely to receive 'standard' therapy. Socioeconomically disadvantaged patients with stage I-II NSCLC have inferior survival independent of therapy.
KW - Chemotherapy
KW - Insurance
KW - Minorities
KW - Radiation therapy
KW - Surgery
KW - Underserved
UR - http://www.scopus.com/inward/record.url?scp=84867538664&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84867538664&partnerID=8YFLogxK
U2 - 10.1016/j.cllc.2012.03.002
DO - 10.1016/j.cllc.2012.03.002
M3 - Article
C2 - 22512997
AN - SCOPUS:84867538664
SN - 1525-7304
VL - 13
SP - 448
EP - 457
JO - Clinical Lung Cancer
JF - Clinical Lung Cancer
IS - 6
ER -